R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Public ClinicalTrials.gov record NCT00021541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Study identification
- NCT ID
- NCT00021541
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Interventions
- tipifarnib Drug
- placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 3 Years to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2001
- Primary completion
- Feb 18, 2009
- Completion
- Feb 18, 2009
- Last update posted
- Apr 16, 2018
2001 – 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (M1149) | Birmingham | Alabama | 35233 | — |
| Children's Hospital Los Angeles, CA (M1118) | Los Angeles | California | 90027 | — |
| Children's Memorial Hospital, Chicago, IL (M1484) | Chicago | Illinois | 60614 | — |
| Johns Hopkins Oncology Center (M1011) | Baltimore | Maryland | 21231 | — |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
| The Children's Hospital, Dana-Farber Cancer Institute, Boston, MA (M1034) | Boston | Massachusetts | 02115 | — |
| St. Louis Children's Hospital, St. Louis, MO (M1123) | St Louis | Missouri | 63110 | — |
| SUNY Upstate Medical University, NY (M1303) | Syracuse | New York | 13210 | — |
| Cincinnati Children's Hospital (FWA 00002988) | Cincinnati | Ohio | 45229 | — |
| Childrens Hospital of Philadelphia, PA (M1257) | Philadelphia | Pennsylvania | 19104 | — |
| Texas Children's Hospital, Houston, TX (M1060) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00021541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2018 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00021541 live on ClinicalTrials.gov.